This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pachner, A.R. Search for Related Content PubMed PubMed Citation Articles by Pachner, A.R. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Neutralizing anti-IFNß antibodies: clarity and confusion

Department of Neurosciences UMDNJ-New Jersey Medical School 185 S. Orange Ave, Newark, NJ 07103

References

• Boz C., Oger J., Gibbs E., Grossberg SE and the Neurologists of the UBC MS Clinic. Reduced effectiveness of long-term interferon-ß treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 2007; 13: 1127—37.[Abstract/Free Full Text]
• Goodin DS, Frohman EM, Hurwitz B. et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977—84.
• Pachner A., Dail D., Pak E., Narayan K. The importance of measuring IFNß bioactivity: monitoring in MS patients and the effect of anti-IFNß antibodies. J Neuroimmunol 2005; 166: 180—8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pachner A., Narayan K., Pak E. Multiplex analysis of expression of three IFNß-induced genes in antibody-positive MS patients. Neurology 2006; 66: 444—6.[Abstract/Free Full Text]
• Sorensen PS, Ross C., Clemmesen KM et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184—91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Malucchi S., Sala A., Gilli F. et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031—37.[Abstract/Free Full Text]
• Soelberg Sorensen P, Koch-Henriksen N., Ross C., Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33—9.[Abstract/Free Full Text]
• Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA MRI and clinical activity in MS patients after terminating treatment with interferonß. Multiple Sclerosis 2000; 6: 86—90.[Abstract/Free Full Text]
• Rudick R. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology 2003; 61: S29—S32.[Free Full Text]
• Filippini G., Munari L., Incorvaia B. et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545—52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rudick RA, Simonian NA, Alam JA et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1206—8.[Free Full Text]
• Sorensen PS, Deisenhammer F., Duda P. et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817—27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Oger J. (Guest Editor) Clarifying the issues on antibodies to interferon in MS: Views from industry and four academics. Mult Scler 2007; 13 (Suppl 1): s5—s62.[Web of Science]
• Farrell RA, Giovannoni G. Measuring and management of Antiferon Beta Antibodies in subjects with Multiple Sclerosis. Mult Scler 2007; 13: 567—577.[Abstract/Free Full Text]
• Pachner AR An improved ELISA for screening for neutralizing anti-IFNß antibodies in MS patients. Neurology 2003; 61: 1444—6.[Abstract/Free Full Text]

Multiple Sclerosis, Vol. 13, No. 9, 1081-1082 (2007)
DOI: 10.1177/1352458507082093


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pachner, A.R. Search for Related Content PubMed PubMed Citation Articles by Pachner, A.R. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?